Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anpede.2024.503721 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knuckle pads in adolescents: the role of microtrauma.
An Pediatr (Engl Ed)
December 2024
Servicio de Pediatría, Unidad Local de Salud de Médio Ave, Vila Nova de Famalicão, Portugal.
Palmoplantar keratoderma, knuckle pads, and syndactyly associated with a new missense variant in the SLURP1 gene.
Int J Dermatol
December 2024
Department of Dermatology, Hospital del Mar, Barcelona, Spain.
CASTing the net wider: A case report of PLACK syndrome associated with dilated cardiomyopathy.
Pediatr Dermatol
November 2024
Department of Internal Medicine, Division of Dermatology, Dell Medical School, University of Texas, Austin, Texas, USA.
Article Synopsis
- PLACK syndrome is a rare genetic skin condition associated with symptoms like peeling skin, white nails, and knuckle pads, caused by mutations in the CAST gene that affects a specific protease.
- This case report discusses a patient with PLACK syndrome who showed unusual palm hyperkeratosis and developed serious heart issues, specifically cardiomyopathy.
- The report emphasizes the need to understand how CAST mutations can affect heart health and highlights the possible links between PLACK syndrome and cardiac problems.
A Rare Case on Capecitabine Induced Acquired Palmoplantar Keratoderma.
Clin Cosmet Investig Dermatol
December 2023
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.
Acquired palmoplantar keratoderma (PPK) is a non-hereditary hyperkeratosis of the palms and soles that is caused by various factors, including chemotherapeutic agents. The purpose of this case report is to present a rare case of acquired PPK caused by the chemotherapeutic agent capecitabine. A 54-year-old female complained of painful erythematous plaques on her palms and soles with history of consuming capecitabine.
View Article and Find Full Text PDFArticle Synopsis
- Collagenase clostridium histolyticum (CCH) is a non-surgical treatment for Dupuytren Disease, but recurrence rates are high and predictors of these outcomes are not well understood.
- A study of 74 patients over 5 years showed a 67% recurrence rate after CCH treatment, with no correlation found between the Dupuytren Diathesis Score (DDS) and recurrence.
- However, the presence of knuckle pads was linked to a lower risk of recurrence, and overall patient satisfaction with CCH treatment was reported as high.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!